Mahmoud Mahmoudian, Phd, Frs Email & Phone Number

Cambridge, Ma, Us

Venture Studio – innovators in catalyzing translation of the next generation nature-inspired AI-driven targeted therapies into cures to improve human health.

RNA Therapies – artificial intelligence-based precision medicines for neurological disorders.

Princeton , Nj, Us

mini-CAR – the first AI-designed mini-CAR therapeutics to revolutionize cancer and hereditary disease treatment.

Mountain View, California, Us

Immuno-oncology – the next generation AI-generated cancer medicines targeting tumor microenvironment.

Immunotherapy – allogeneic cell therapies.

Watertown, Ma, Us

Cell Therapy – controllable CAR-T cells in solid tumors.

Mclean, Virginia, Us

Venture Fund – company building, venture creation and biotech investments operating across its portfolio incubating disruptive scientific breakthroughs.* AI Proteins – Chief Business Officer (mini-proteins)* MANA Therapeutic – President, CEO (cellular medicines)* Dynamic Cell Therapies – Chief Business Officer (tunable CAR-T)

Marlborough, Massachusetts, Us

Headed innovation hubs worldwide – Chief Science Scout leading venture investments and external partnerships with academia, syndicating with venture capital to develop new biology, technologies and treatments in cancer including oRNA – circular RNA ($200M series B).Venture Fund – launched corporate fund as an early-stage investor. Executive Committee – chaired science and investment committees. Worked with board members, scientific advisory board, cross-functional teams (R&D, clinical, regulatory, manufacturing, commercial) to expedite discovery, development and regulatory approvals of novel modalities (RNA therapies, gene editing, artificial intelligence) including Manzara Therapeutics – generative AI.Venture Creation – raised $100M in capital to build academic and venture hubs. Established oncology research alliance with Columbia, Wistar Institute, Harvard and Dana-Farber Cancer Institute. Invested in MPM Capital oncology fund as Limited Partner – member of investor committee. Dana-Farber Innovations Research Fund – $10M investment to discover breakthrough medicines. Roivant – launched Sumitovant in a $3B acquisition (Myovant, Urovant, Enzyvant, Altavant, Spirovant).

St-Prex, Ch

Innovation Hub – global Head reporting to President. Led scientific, commercial due diligence teams to scout, evaluate and develop novel medicines including Rebyota®, the first FDA approved microbiome-based treatment for C. difficile infections.Business Development – raised $100M in capital, formed Trizell SA to commercialize immunotherapy pipeline. Levo Therapeutics – spun off NewCo in rare diseases, raised $40M series A, sold to Acadia Pharma. Ferring Microbiome Institute – joint venture with Intralytix and Karolinska Institute to map human gut microbiota. TxCell – in-licensed OvaSave® (Crohn’s disease), developed and sold to Sangamo for $84M. Launched FerGene – developed Adstiladrin® for bladder cancer with $570M investment from Blackstone.External Research – led investments and incubation of disruptive platforms (mRNA vaccines, phage and gene therapies) for celiac disease, prostate, ovarian and pancreatic cancers including Viventia Bio – antibody drug conjugate, acquired by Eleven Biotherapeutics.

Merck Bioventures – led scouting, scientific search and evaluation, licensing, venture investments in vaccines and biologics.Business Development – structured deals in immuno-oncology, autoimmune disorders and infectious diseases including acquisition of Sirna – RNA interference to aid drug discovery ($1.1B). GlycoFi – yeast glycosylation platform for antibody production ($400M). Lonza – joint venture for biomanufacture of pneumococcal vaccine (Pneumovax®).External Research – chaired governance committees that included technical transfer, manufacturing and alliance management for GMP scale up and BLA submissions. Led global development teams with multiple FDA approvals and launches – meningococcal vaccine (MenB®), human papillomavirus vaccine (Gardasil®), shingles vaccine (Zostavax®).

Midland, Michigan, Us

Headed research and development across five sites (US, UK, France, China, Japan) generating $600M sales with 200 reports. Directed global teams that developed products for bio-pharmaceutical applications in emerging markets (China, India, Brazil).Innovation Hub – established biosciences footprint. Identified new technologies for joint ventures, co-development or out-licensing deals with strategic partners. Fresenius – diagnostic kits for sepsis. Sanofi – streamlining insulin production. Genzyme – ophthalmology, biodegradable polymers for targeted delivery. Millipore – development and manufacture of biologics ($100M).Executive Committee – chaired corporate growth at Rohm & Haas (reported to CEO). Member of Emerging Technology Board of Directors. Dow acquired Rohm & Haas in 2007 for $16B.

Kingsport, Tennessee, Us

Recruited by CEO to build biotech hub. Headed global research, implemented strategies for corporate growth and diversification.Innovation Hub – developed broad pipeline, infrastructure that included strategic alliances, targeted divestitures, in/ out-licensing, acquisitions and venture investments. Athenix – $1M investment, sold to Bayer for $400M. Centrus – spun off diagnostics NewCo, sold to Neogene. Altus – acquisition, Enzyme Replacement Therapy for cystic fibrosis. Genencor – metabolic engineering, 51% equity investment, sold to Danisco for $475M.Corporate Development – chaired Biotechnology Board of Directors and investment committee.

Brentford, Middlesex, Gb

Led global cross-functional drug development teams (discovery, preclinical, clinical, biomanufacturing) in vaccines, biologics and small molecules. FDA approvals – hepatitis B (Lamivudine®), influenza (Relenza®), HIV (Epivir®, Abacavir®, Trizivir®), leukemia (Zygara®), shingles vaccine (Shingrix®), pneumococcal vaccine (Synflorix®).R&D – developed GMP fermentation and biological processes (microbial and mammalian cell cultures, natural products) for multi-ton scale product launches including Relenza® using immobilized recombinant aldolase with 2500 continuous enzyme reuse.External Research – chaired steering committees for key alliances (Amgen, Gilead, Vertex) in neuroscience, anti-infectives, cardiometabolic and inflammatory disorders.

Doctor Of Philosophy (Phd). Master Of Science (Msc)

Marketing